Breast cancer in a male with ankylosing spondylitis treated with TNFalpha antagonists.

doi:10.1016/j.jbspin.2008.12.004

Article

Breast cancer in a male with ankylosing spondylitis treated with TNFalpha antagonists.

Joint bone spine - 1 Jul 2009

El Mansouri Laila, Couchouron Tifenn, Le Roux Guillaume, Dugast Catherine, Burtin Françoise, Albert Jean-David, Perdriger Aleth, Hassouni Najia Hajjaj, Chalès Gérard

Abstract excerpt

A 72-year-old male with a 4-year history of TNFalpha antagonist therapy (infliximab and etanercept) for ankylosing spondylitis was diagnosed with breast cancer. He had a family history of breast cancer. The low incidence and considerable severity of breast cancer in males, genetic risk factors, and potential role for TNFalpha antagonist therapy are discussed.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Etanercept

Share to Genes, BRCA2

Share to Immunoglobulin G

Share to Infliximab

Share to Receptors, Tumor Necrosis Factor

Share to Spondylitis, Ankylosing

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Breast cancer in a male with ankylosing spondylitis treated with TNFalpha antagonists.PMID 19457692Read

Review of 54-year-old man with breast cancer after prolonged testosterone therapy.Semantic proximity Read

The Epidemiology of Male Breast Cancer.Semantic proximity Read

An updated review of epidemiology, risk factors, and management of male breast cancer.Semantic proximity Read

A 64-Year-Old Man With Germline BRCA2-Mutated Breast Cancer: Known and Unknown Aspects of Male Breast Cancer.Semantic proximity Read

Male breast cancer.Semantic proximity Read

Breast cancer in men.Semantic proximity Read

Male Breast Cancer: Epidemiology and Risk Factors.Semantic proximity Read

Male breast cancer: a rare disease that might uncover underlying pathways of breast cancer.Semantic proximity Read